[PDF] Top 20 Institucionalidad en el Paisaje Cultural Cafetero PCC
Has 9159 "Institucionalidad en el Paisaje Cultural Cafetero PCC" found on our website. Below are the top 20 most common "Institucionalidad en el Paisaje Cultural Cafetero PCC".
Radium 223 dichloride for prostate cancer treatment
... death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone ...lesions. Radium-223 dichloride has been approved for the treatment of metastatic ... See full document
30
A population based study of the use of radium 223 in metastatic castration resistant prostate cancer: Factors associated with treatment completion
... Radioisotopes, such as the beta-emitter strontium 89 (Sr89), have been used in the past to decrease the rate of progression of new site of pain either on its own, or in combination with external beam radiotherapy. ... See full document
19
Pain response in a population based study of radium 223 (Ra223) for metastatic castration resistant prostate cancer
... microenvironment. 9-11 Any or all of these mechanisms could contribute to pain relief yet not all would lead to a decline in ALP, which is primarily a marker of osteoblastic activity in this context. 12 Our data suggest ... See full document
15
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
... castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; under- standing risk factors will improve ... See full document
48
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
... breast cancer with radiologically confirmed bone-dominant disease with or without metastases in soft tissue, lymph nodes, and/or skin, with C1 nonirradiated bone metastasis on bone scintigraphy [planar imaging ... See full document
21
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
... castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; under- standing risk factors will improve ... See full document
38
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
... of radium-223 patients and 45% of placebo patients were minimally symptomatic, with no pain or mild pain and no opioid use; of these, 4% of radium-223 patients and 1% of placebo patients were ... See full document
11
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
... denosumab demonstrated improvements in prostate-specific antigen (PSA) levels, overall disease progression, or overall survival. Thus, while these are bone-targeted agents, they may have a greater effect on bone ... See full document
17
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
... 3.0. Treatment- emergent AEs (TEAEs) included all AEs that started after the first injection up to 12 wk after the last ...considered treatment related by the ... See full document
71
<p>Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome</p>
... the treatment of ...Odette Cancer Centre [Toronto], Juravinski Hospital [Hamilton], and Lakeridge Health [Oshawa]), and at Princess Margaret Cancer Centre [Toronto] from January 2015 to October ... See full document
41
The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.
... 14. Segall GM. PET/CT with sodium 18F-fluoride for management of patients with prostate cancer. J Nucl Med. 2014;55:531-3. doi:10.2967/jnumed.113.133546. 15. Mick CG, James T, Hill JD, Williams P, Perry M. ... See full document
165
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
... proportional treatment effect (PTE) [12]. PTE describes how much of the treatment effect on OS is explained by biomarker ...with treatment (radium-223) plus the surrogate marker (tALP, ... See full document
17
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
... established radium-223 efficacy and safety in CRPC patients with bone metastases [18, ...With radium-223, versus placebo, OS improved significantly (median ...favored radium-223 ... See full document
10
Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer
... the treatment with Radium-223 at the INMM in order to improve the quality of the thera- peutic ...this treatment, the patients create just one homogenous group of men with ...the ... See full document
5
Pain response in a population based study of radium 223 (Ra223) for metastatic castration resistant prostate cancer
... As ALP levels can reflect bone activity, we postulated that the pain response during Ra223 treatment may correlate with ALP response. Our study failed to show such a relation- ship, which is the second major ... See full document
9
Radium-223 for the treatment of castration-resistant prostate cancer
... the radium-223 arm had a significant improvement in their quality of life as assessed by the FACT-P (Functional Assessment of Cancer Therapy-Prostatic) score (25% versus 16%, P = ...0.02). ... See full document
5
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.
... Regular communication between referring physicians and the treating nuclear medicine physicians will establish solid working relationships and keep all parties informed of pa- tients’ progress. This could be achieved via ... See full document
14
Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
... 68 prostate-specific membrane antigen (Ga 68 PSMA) positron electron tomography (PET) in the evaluation of patient suitability for Ra-223 therapy over bone ... See full document
36
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
... From November 2014 through March 2017, a total of 25 patients were treated with radium-223. Of these, 6 (24%) reported VAS ,4 at baseline evaluation. Among these, none had a total ALP .220 U/L. In addition, ... See full document
5
Current approaches to incorporation of radium-223 in clinical practice.
... of radium-223 in order to con fi rm there has been no extraskeletal disease progression ...in prostate cancer and cannot yet be recommended for use in routine clinical ...to ... See full document
38
Related subjects